|Assessment Status||Assessment Process Complete|
|Indication||For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.|
|Full submission received from Applicant||31/07/2009|
|NCPE assessment completed||01/02/2010|
|NCPE assessment outcome||Reimbursement Recommended|
The review group consider that prasugrel, co-administered with aspirin, is cost-effective in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention in the Irish healthcare setting.